Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Multi-center retrospective study shows non-significant SRE reduction with Dara-based tx (HR=0.44, 95% CI 0.17-1.15, P=0.09); subgroup analyses find significant benefit in pts without baseline hypercalcemia and with standard-risk.”
Title: The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study
Authors: Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng
You can read the Full Article in BMC Cancer.
You can find more posts featuring Robert Orlowski on OncoDaily.
